AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.
You may also be interested in...
Symbicort NDA On-Track Despite FDA Data Request, AstraZeneca Says
FDA has requested additional chemistry, manufacturing and control data for Symbicort inhalation delivery device. While AstraZeneca does not believe this will significantly delay product development, the company does have a back-up strategy for a slightly modified device.
Symbicort NDA On-Track Despite FDA Data Request, AstraZeneca Says
FDA has requested additional chemistry, manufacturing and control data for Symbicort inhalation delivery device. While AstraZeneca does not believe this will significantly delay product development, the company does have a back-up strategy for a slightly modified device.
Liraglutide Phase III Diabetes Program Delayed Until 2005
Novo Nordisk expects its glucagon-like peptide-1 analog liraglutide to enter Phase III trials in 2005